search
Back to results

An Evaluation of Divalproex vs. Olanzapine for Alcohol Abuse Relapse Prevention in Patients With Bipolar Disorder

Primary Purpose

Bipolar Disorder

Status
Withdrawn
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
divalproex or olanzapine
Sponsored by
Mayo Clinic
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bipolar Disorder focused on measuring Bipolar, Alcohol

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria: Age 18-65 DSM-IV criteria for manic episode based on the SCID (Spitzer 1996) DSM-IV criteria for alcohol dependence or abuse based on the SCID. Meeting criteria for polysubstance dependence or abuse will not be exclusionary. Alcohol dependence/abuse confirmed by corroboration. Negative urine pregnancy test l Exclusion Criteria: Inability to give informed consent Liver function tests greater than 3X the upper limit of normal History of adverse reaction to divalproex sodium or olanzapine History of seizure other than directly associated with prior alcohol withdrawal History of major head trauma with LOC > 5 minutes or skull fracture History of hypertension, neurologic illness Active hepatitis, hepatic encephalopathy, or history of pancreatitis Not practicing a reliable form of birth control

Sites / Locations

  • UCLA Neuropsychiatric Institute

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
September 13, 2005
Last Updated
May 29, 2015
Sponsor
Mayo Clinic
Collaborators
University of California, Los Angeles
search

1. Study Identification

Unique Protocol Identification Number
NCT00221481
Brief Title
An Evaluation of Divalproex vs. Olanzapine for Alcohol Abuse Relapse Prevention in Patients With Bipolar Disorder
Official Title
An Evaluation of Divalproex vs. Olanzapine for Alcohol Abuse Relapse Prevention in Patients With Bipolar Disorder
Study Type
Interventional

2. Study Status

Record Verification Date
February 2009
Overall Recruitment Status
Withdrawn
Why Stopped
Lack of recruitment
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
March 2006 (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mayo Clinic
Collaborators
University of California, Los Angeles

4. Oversight

5. Study Description

Brief Summary
This study will evaluate how effective mood stabilizers are in the treatment of bipolar disorder with comorbid alcoholism
Detailed Description
Bipolar affective disorder is a medical illness with substantial morbidity and mortality. Further fueling the severity of this illness is the substantial co-occurrence with substance abuse that together poses an enormous public health problem. This study will evaluate the efficacy of divaproex sodium (DVPX) vs. olanzapine (ZYP) vs. for alcohol relapse prevention and secondary mood stabilization. Bipolar patients who are actively drinking will be randomized to either Depakote ER ® (flexible dose schedule up to 2500 mg) or Zyprexa® (flexible dose schedule up to 20 mg). Adjunctive benzodiazepine will be utilized for the treatment of alcohol withdrawal and as an adjunct anxiolytic during the early titration of DVPX and ZYP. Patients who, after 2 weeks, have stabilized will continue in the prophylaxis study which will last up to 46 weeks. Flexible dose scheduling and adjunctive antidepressant treatment as clinically indicated will be done to maximize tolerability, treatment compliance, and mood stability. The primary outcome measure will be alcohol abuse relapse which will be defined, a priori, as 5 drinks in a 24 hour period. Patients who have a relapse as such defined will be terminated from the study. Secondary alcohol outcome measures (i.e. number of drinking days, % drinking days per month, standard drinks per drinking occasion, craving) will be assessed through the time-line follow-back method. Secondary outcome measures of mood stabilization (major mood relapse and adjunctive medication) will be assessed by prospective life charting.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bipolar Disorder
Keywords
Bipolar, Alcohol

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
Single
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
divalproex or olanzapine

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18-65 DSM-IV criteria for manic episode based on the SCID (Spitzer 1996) DSM-IV criteria for alcohol dependence or abuse based on the SCID. Meeting criteria for polysubstance dependence or abuse will not be exclusionary. Alcohol dependence/abuse confirmed by corroboration. Negative urine pregnancy test l Exclusion Criteria: Inability to give informed consent Liver function tests greater than 3X the upper limit of normal History of adverse reaction to divalproex sodium or olanzapine History of seizure other than directly associated with prior alcohol withdrawal History of major head trauma with LOC > 5 minutes or skull fracture History of hypertension, neurologic illness Active hepatitis, hepatic encephalopathy, or history of pancreatitis Not practicing a reliable form of birth control
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mark A Frye, MD
Organizational Affiliation
University of California, Los Angeles
Official's Role
Principal Investigator
Facility Information:
Facility Name
UCLA Neuropsychiatric Institute
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States

12. IPD Sharing Statement

Learn more about this trial

An Evaluation of Divalproex vs. Olanzapine for Alcohol Abuse Relapse Prevention in Patients With Bipolar Disorder

We'll reach out to this number within 24 hrs